Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
-
If you are wondering whether InSilico Medicine Cayman TopCo at HK$59.45 is priced attractively or not, this article will walk you through what the current share price might be implying about its value.
-
The stock is up 1.5% over the last 7 days, has seen a 4.3% decline over the last 30 days, and is up 58.2% year to date. These moves may have shifted how investors see its potential and risk profile.
-
Recent coverage has focused on InSilico Medicine Cayman TopCo as a listed player in the pharmaceuticals and biotech space in Hong Kong, with attention on how its pipeline, partnerships and technology positioning compare with peers. This backdrop helps explain why the market has been reassessing the stock and could be influencing the recent mix of short term gains and pullbacks.
-
The company currently has a valuation score of 2 out of 6, which suggests some checks screen as undervalued while others do not. Next, we will look at how different valuation methods line up on InSilico Medicine Cayman TopCo and then finish with a broader way to think about its valuation story.
InSilico Medicine Cayman TopCo scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown .
Approach 1: InSilico Medicine Cayman TopCo Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting them back to today to reflect risk and the time value of money.
For InSilico Medicine Cayman TopCo, the latest twelve month free cash flow (FCF) is a loss of $65.17 million. Analyst and model projections then move this towards positive territory, with FCF reaching $296.09 million in 2030. The model uses a 2 Stage Free Cash Flow to Equity approach, with analyst inputs up to 2030 and further years extrapolated by Simply Wall St to build a ten year cash flow path.
When these projected cash flows are discounted back and summed, the model arrives at an estimated intrinsic value of HK$135.69 per share. Compared with the current share price of HK$59.45, this estimate suggests the shares trade at a 56.2% discount on this DCF measure.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests InSilico Medicine Cayman TopCo is undervalued by 56.2%. Track this in your watchlist or portfolio , or discover 225 more high quality undervalued stocks .
Approach 2: InSilico Medicine Cayman TopCo Price vs Book
For companies where earnings can be volatile or negative, price-based metrics that lean on the balance sheet, like the P/B ratio, can give you a clearer view of how the market values the underlying net assets.
In general, higher growth expectations and lower perceived risk support a higher "normal" valuation multiple, while slower growth and higher uncertainty tend to justify a lower one. That idea applies across all common ratios, including P/B.
InSilico Medicine Cayman TopCo currently trades on a P/B ratio of 6.37x. This is above the Life Sciences industry average P/B of 2.51x and also above the peer group average of 4.38x, which suggests the market is attaching a richer price tag to its equity than to many comparable names.
Simply Wall St's Fair Ratio is a proprietary estimate of what a company's preferred multiple might be, after accounting for factors like earnings growth profile, industry, profit margins, market value and specific risks. Because it blends these inputs, it can be more tailored than a simple comparison with peers or the broad industry, which only shows where the stock sits on a basic relative scale.
For InSilico Medicine Cayman TopCo, the Fair Ratio estimate is not available, so it is not possible to draw a firm conclusion on whether the current 6.37x P/B looks high, low or about right relative to that model.
Result: ABOUT RIGHT
P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 100 top founder-led companies .
Upgrade Your Decision Making: Choose your InSilico Medicine Cayman TopCo Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. These are simply your story about a company, connected directly to your assumptions for future revenue, earnings, margins and the fair value you think those numbers support.
On Simply Wall St's Community page, used by millions of investors, a Narrative lets you tie InSilico Medicine Cayman TopCo's business story to a forecast and a fair value. You can then compare that fair value with the current share price to help you decide whether you see it as an opportunity or something to watch.
Because Narratives are updated automatically when new information arrives, such as fresh earnings or news, you always see your thesis and estimated fair value in the context of the latest data rather than a static snapshot.
For example, some investors on the Community page may build Narratives for InSilico Medicine Cayman TopCo that support a very high fair value, while others use more conservative assumptions that lead to a much lower fair value. Seeing that range can help you clarify where your own view sits and how confident you feel about it.
Do you think there's more to the story for InSilico Medicine Cayman TopCo? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 3696.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
